Cagrilintide
A long-acting amylin analogue being developed in combination with semaglutide (CagriSema) for enhanced weight loss.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Cagrilintide?
Cagrilintide is a long-acting acylated amylin analogue designed for once-weekly dosing. It is being developed by Novo Nordisk both as a standalone treatment and in combination with semaglutide (CagriSema). The combination has shown weight loss of up to 22.7% in Phase III trials, potentially matching or exceeding tirzepatide.
Why People Talk About It
Enhanced weight loss when combined with semaglutide
EmergingAppetite suppression through amylin pathway
EmergingPotential next-generation obesity treatment
EmergingHow It Works
Cagrilintide mimics amylin, a natural hormone that makes you feel full after eating. Combined with semaglutide (which mimics GLP-1), the two hormones work through different brain pathways to provide stronger appetite suppression than either alone.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Not yet FDA-approved
- • GI side effects similar to GLP-1 class
- • Long-term safety data still accumulating
What We Don't Know
Phase III data is being collected. Long-term safety and cardiovascular outcomes are not yet established.
Published Research
22 studiesComparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
Amylin analogs for the treatment of obesity without diabetes: present and future
Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance
Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide
Development of Cagrilintide, a Long-Acting Amylin Analogue
Cagrilintide plus semaglutide for obesity management
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
Semaglutide
StrongBeginnerA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, one of the most widely prescribed peptide drugs.
Pramlintide
StrongAn FDA-approved synthetic analogue of amylin used alongside insulin for diabetes, also studied for weight management.
Tirzepatide
StrongBeginnerA dual GIP/GLP-1 receptor agonist FDA-approved for diabetes and weight management, producing the largest weight loss seen in clinical trials.
Quick Facts
- Class
- Amylin Analogue
- Evidence
- Emerging
- Safety
- Moderate Data
- Updated
- Mar 2026
- Citations
- 22PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician